Results: In present case, pembrolizumab are effective to both of lung cancer and gastric cancer. It is believed that environmental factors such as smoking are cause of multiple cancers and related to high numbers of mutation of tumor genome. As smoking is one of the prognosis factor of anti-PD-1 therapy, the present case might demonstrate an effectiveness of pembrolizumab even for gastric cancer though its TPS is negative.
Conclusion: ICI such as pembrolizumab might be effective in synchronous multiple cancers, especially in smoking patients. Methods: Patients with EGFR mutation-positive advanced NSCLC who visited a tertiary referral center from December 1, 2013, to November 30, 2017, were analyzed retrospectively. They received gefitinib, erlotinib, or afatinib until disease progression, death, or intolerable adverse events.
The cumulative incidence of subsequent BM of initial non-BM patients, progression-free survival (PFS), and overall survival (OS) of the BM and non-BM patients were estimated and compared using the Kaplan-Meier and log-rank tests.
Results: 306 NSCLC patients were enrolled, with 116, 75, and 115 receiving first-line gefitinib, erlotinib, and afatinib, respectively. The afatinib group had a better PFS (12.7 vs 9.8 months; HR 0.59, P = 0.001) and OS (39.1 vs 22.0 months; HR 0.64, P = 0.035) than the gefitinib group. Afatinib tended to provide better BM prevention than gefitinib (BM cumulative incidence, HR 0.49; 95% CI: 0.34-0.71, P < 0.001) according to a Cox model adjusted for possible confounders. Patients with initial BM had a shorter PFS (P < 0.001) and OS (P = 0.015) than those without initial BM. Among the former, there were no differences in median PFS (P = 0.34) and median OS (P = 0.46) in the three EGFR-TKI groups.
Conclusion: Our data suggested that, compared to gefitnib, afatinib provided significant benefits in terms of PFS and OS in treating BM. Both had the same effectiveness in preventing subsequent BM. Background and Aims: Primary Pulmonary Synovial Sarcoma is a highly aggressive and extremely rare tumor. A 31-year-old female, Overseas Filipino Worker, underwent routine chest radiograph wherein a left sided pleural effusion was found incidentally. The patient denied any respiratory symptoms. She had pleural biopsy and was advised for further work up however she decided to go back to the Philippines. Few days prior to admission, she had difficulty of breathing prompted consult to our institution and was subsequently admitted. The Patient arrived in the emergency room in cardiopulmonary distress. She was pale and chest examination revealed asymmetrical chest expansion, no retractions, absent tactile and vocal fremitus and absent breath sounds on the left lung field.
Methods: To report a case of 31 years old asymptomatic female with primary Pulmonary Synovial Sarcoma.
Results: A massive pleural effusion with contralateral mediastinal shifting was seen on Chest radiograph. On Contrast Enhanced Computed Tomography of thorax showed multiple heterogeneous lesion of the pleural fluid contained within the thickened contrast-enhanced rim septations occupying almost the entire left hemithorax. Patient underwent videoassisted thoracoscopic surgery with frozen section biopsy and chest tube thoracostomy. Pleural fluid analysis revealed predominance of segmenters (60%), exudative with haemorrhagic pleural fluid. Furthermore, the pleural fluid was negative for acid fast bacilli and no growth on culture.
Histopathologic findings were consistent with Monophasic Synovial Sarcoma. Immunohistochemical (IHC) analysis was BCL-2, CD99 positive, and show focal positivity with Epithelial Membrane Antigen (EMA), Cytokeratin (CK) 7, Cytokeratin AE1/AE3 while CD8, Cytokeratin 5/6, desmin,
